Report Highlights

Quasi drugs at a turning point: Market Overview

The global quasi drug market stands at USD 48.7 billion in 2024, shaped predominantly by Asia Pacific regulatory architectures—most notably Japan's Pharmaceutical and Medical Device Act—that formally distinguish this product category from both cosmetics and prescription drugs. The market has expanded steadily over the past decade on the strength of consumer premiumisation in personal care, growing awareness of medicated topical products, and rising disposable incomes across East and Southeast Asia. Japan remains the definitional anchor, but the category concept is gaining regulatory traction in South Korea, Taiwan, and increasingly in Gulf Cooperation Council markets seeking structured middle-ground product classifications.

The current moment marks a structural turning point because two simultaneous forces are converging: digital commerce is dismantling the pharmacy-channel dependency that historically constrained quasi drug distribution, and post-pandemic self-care spending has permanently elevated consumer willingness to pay for products with credible clinical positioning. Regulatory bodies in four new jurisdictions initiated formal quasi drug or functional cosmetic classification consultations between 2022 and 2024, signalling that the category framework is globalising. This transition from a Japan-centric niche to a multi-jurisdictional commercial standard is the primary structural shift defining the decade ahead for this market.

Key forces shaping quasi drug growth

Three forces are driving measurable revenue expansion in this market. First, the ageing demographic across Japan, South Korea, and China is generating sustained demand for scalp health, hair-loss prevention, and medicated skin products—all classic quasi drug segments. Japan's population aged 65 and above exceeded 29% in 2023, directly amplifying demand for minoxidil-classified hair tonics and anti-itching medicated shampoos. This demographic force translates directly into revenue because quasi drug status commands a 25–40% price premium over standard cosmetics, and older consumers exhibit higher brand loyalty and repeat purchase rates than younger cohorts.

Second, the cross-border e-commerce surge—specifically daigou trade flows from Japan to China—has made quasi drug brand equity an exportable asset even without formal regulatory approval in destination markets. Platforms such as Tmall Global and Amazon Japan have created shadow distribution channels that generate genuine revenue while formal market entry is pending. Third, male grooming acceptance in East Asia is expanding the addressable quasi drug market beyond its traditional female-skewed base. South Korea's male skincare penetration reached 63% in 2023, and medicated acne and skin-brightening preparations classified as quasi drugs are the highest-margin sub-segment within that growth trajectory.

Barriers and risks in the quasi drug market

The most consequential structural barrier is regulatory fragmentation. Unlike pharmaceuticals, which align under ICH guidelines, or cosmetics, which broadly follow EU or ASEAN frameworks, quasi drugs have no international harmonisation treaty. A product approved under Japan's PMDA as a quasi drug requires entirely separate dossiers, ingredient justifications, and labelling compliance for South Korea's MFDS, Taiwan's TFDA, and prospective Gulf markets. This creates a duplication cost that disproportionately burdens mid-sized manufacturers and prevents the category from scaling globally at the pace consumer demand warrants. The structural nature of this barrier means it will not resolve within the forecast period without active intergovernmental effort, which is not currently scheduled.

The cyclical risk most dangerous to the near-term growth thesis is a consumer trading-down response to sustained inflation in Japan and South Korea. Quasi drugs occupy a premium price tier, and household consumption data from both markets showed personal care expenditure softening in 2022–2023 before recovering. A second inflationary cycle—driven by yen weakness and raw material repricing—risks pushing consumers toward non-medicated alternatives that are meaningfully cheaper. This cyclical risk is more immediately threatening than the structural fragmentation barrier because it operates on a one-to-two-year time horizon and directly compresses the margin profile of market leaders including Shiseido and Lion Corporation.

Emerging opportunities in quasi drugs

The most credible near-term opportunity is the formalisation of quasi drug or equivalent classifications in Gulf Cooperation Council markets, particularly Saudi Arabia and the UAE. Both countries have active SFDA and MOHAP regulatory modernisation programmes, and their large expatriate East Asian populations have already established consumer demand for Japanese quasi drug products through informal import channels. The condition that must be met for this opportunity to materialise is a bilateral regulatory dialogue between Japan's PMDA and Saudi SFDA—preliminary discussions were confirmed in 2023 and a framework agreement is expected before 2027.

A second opportunity lies in OTC quasi drug line extensions by Japanese pharmaceutical companies targeting the medicated oral care segment. The whitening toothpaste and medicated mouthwash sub-segments are structurally underpenetrated relative to hair and skin quasi drugs, yet command equivalent price premiums. Lion Corporation's Systema and Sunstar's GUM brands already hold quasi drug classification for specific oral care SKUs, but neither has executed a full portfolio upgrade to quasi drug status. The condition required is a confirmed consumer willingness-to-pay signal—current survey data from Japan's 2024 oral care sentiment studies provide that confirmation, making this a 12-to-24-month execution window rather than a long-range aspiration.

Investment case: Bull, bear, and what decides it

The bull case rests on three specific catalysts: successful regulatory export of the quasi drug framework to two or more new jurisdictions by 2027, continued premiumisation of personal care in China and Southeast Asia absorbing Japanese brand equity at scale, and male grooming market expansion sustaining above-category growth in South Korea. Under these conditions, the market reaches USD 89.3 billion by 2034 at a 6.3% CAGR, with disproportionate value accruing to vertically integrated Japanese players—specifically Kao and Rohto—who control ingredient science, regulatory dossiers, and retail relationships simultaneously. Margin expansion follows because quasi drug premiums widen as the classification earns global credibility.

The bear case centres on three specific risks that individually manageable but collectively decisive: yen depreciation beyond 160 per dollar structurally inflating input costs for Japanese manufacturers without equivalent export price recovery; Chinese regulatory tightening under the 2023 cosmetics law creating a five-year market access void that eliminates the largest assumed growth market; and a generational shift in younger Asian consumers toward clean-label, non-medicated products that erodes the quasi drug premium positioning. Under this scenario, the market stalls below USD 70 billion by 2034, volume growth occurs but margin compression is severe, and consolidation accelerates as smaller players exit the category entirely.

The single swing variable is China's regulatory posture toward imported quasi drugs and functional cosmetics from Japan. China represents the largest consumer base geographically proximate to the category's origin market, and its 2023 ingredient registration overhaul is simultaneously the biggest barrier and the biggest latent demand signal. If Beijing moves toward a bilateral recognition pathway with Japan's PMDA—under pressure from domestic consumer demand and trade negotiation dynamics—the bull case locks in by 2028. If China maintains its current restrictive stance or tightens further, the bear case prevails regardless of how well every other market performs. No other variable carries equivalent weight.

Market at a Glance

Regional performance: Where quasi drugs are growing fastest

Asia Pacific is the largest revenue contributor by a decisive margin, accounting for over 78% of global quasi drug market value in 2024, with Japan alone representing the definitional and commercial core of the category. Japan's regulatory infrastructure, established brand portfolios, and pharmacy channel density make it structurally irreplaceable as the market anchor. South Korea is the fastest-growing developed market within the region, driven by functional cosmetics regulatory alignment and a male grooming surge that has expanded the addressable quasi drug consumer base by an estimated 18 million adults since 2019. China contributes meaningful volume through grey market imports and bonded zone purchases, but formal market revenue remains constrained by the 2023 regulatory overhaul.

Outside Asia Pacific, North America and Europe represent nascent but directionally positive markets. The United States has no formal quasi drug classification—products fall under FDA OTC drug or cosmetic rules—but Japanese-heritage brands like Shiseido and Kose are successfully repositioning medicated product lines under OTC drug claims, capturing quasi drug pricing without quasi drug labelling. Europe follows a similar dynamic, with Germany and France showing the strongest uptake of medicated personal care products that would qualify as quasi drugs under Japanese standards. The Middle East, specifically Saudi Arabia and the UAE, is the highest-potential emerging regional market given its regulatory modernisation trajectory, high per-capita personal care spending, and substantial Asian expatriate consumer base that already purchases quasi drug products through import channels.

Leading Market Participants

• Shiseido Company
• Kao Corporation
• Lion Corporation
• Rohto Pharmaceutical
• Procter and Gamble
• Sunstar Inc.
• Kose Corporation
• Pola Orbis Holdings
• Mandom Corporation
• Unilever

Where is the quasi drug market headed by 2034

By 2034, the quasi drug market is a USD 89.3 billion category that has successfully exported its definitional framework beyond Japan to at least four additional jurisdictions, with South Korea, Saudi Arabia, and two ASEAN markets the most probable additions. The category will be more concentrated, not less, because regulatory complexity systematically advantages incumbents with established dossier infrastructure. Hair care and scalp health remain the largest sub-segment, but oral care quasi drugs will have doubled their share, driven by Lion Corporation and Sunstar executing the portfolio upgrades currently at planning stage. E-commerce will represent over 35% of quasi drug sales by 2034, fundamentally altering the pharmacy channel dominance that defined the category for forty years.

Kao Corporation and Rohto Pharmaceutical are best positioned for 2034 because both combine owned ingredient science with multi-channel distribution capabilities and active regulatory engagement programmes in emerging markets. Kao's investment in bio-based active ingredients directly addresses the clean-label threat to quasi drug premiums, while Rohto's OTC pharmaceutical heritage gives it credibility in new regulatory environments where quasi drug classification requires pharmaceutical-grade evidence standards. Shiseido's prestige positioning remains strong in premium quasi drug skincare, but its heavy dependence on China for luxury personal care revenue introduces execution risk that the more domestically diversified Kao and Rohto portfolios do not carry to the same degree.